Skip to content
Boost Up Blog – Lifestyle
Author:
Aterian, Inc
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
August 20, 2026
Aterian Issues Urgent Call to Action: Only 285,000 Votes or 2.7% Separates Stockholders From Securing Value
July 13, 2026
Both Leading Independent Proxy Advisors Recommend Aterian Stockholders Vote for the Asset Sale
July 8, 2026
Aterian Urges Stockholders to Vote “FOR” All Proposals at the Upcoming Special Meeting of Stockholders on July 10, 2026
July 6, 2026
Aterian, Inc. Announces Mailing of Proxy Materials for Special Meeting of Stockholders
June 18, 2026
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
April 28, 2026
Aterian Provides Update on Strategic Alternatives Process
March 23, 2026